| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/28/2003 | CA2420850A1 Solution formulations having long-term stability |
| 02/27/2003 | WO2003016917A2 Sodium channel regulators and modulators |
| 02/27/2003 | WO2003016915A1 Tumor specific oligosaccharide sequences and use thereof |
| 02/27/2003 | WO2003016567A2 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 02/27/2003 | WO2003016560A2 Methods for diagnosing and treating neoplasias using nf-at transcription factors |
| 02/27/2003 | WO2003016553A2 Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid |
| 02/27/2003 | WO2003016549A2 Nucleic-acid associated proteins |
| 02/27/2003 | WO2003016532A1 Human protooncogene kg-20 and protein encoded therein |
| 02/27/2003 | WO2003016530A1 Novel protein and its dna |
| 02/27/2003 | WO2003016528A2 Oligonucleotide compositions and their use to induce apoptosis |
| 02/27/2003 | WO2003016522A2 Methods and compounds for the targeting of protein to exosomes |
| 02/27/2003 | WO2003016520A1 Anti-aging and wound healing compounds |
| 02/27/2003 | WO2003016515A2 Regulation of human glycerol-3-phosphate acyltransferase-like protein |
| 02/27/2003 | WO2003016514A1 Mullerian inhibiting substance levels and ovarian response |
| 02/27/2003 | WO2003016506A2 Secreted proteins |
| 02/27/2003 | WO2003016505A2 Kgf polypeptide compositions |
| 02/27/2003 | WO2003016502A2 Tramdorins and methods of using tramdorins |
| 02/27/2003 | WO2003016499A2 Combinatorial methods for inducing cancer cell death |
| 02/27/2003 | WO2003016497A2 Molecules for disease detection and treatment |
| 02/27/2003 | WO2003016496A2 Zinc finger binding domains for cnn |
| 02/27/2003 | WO2003016493A2 Transporters and ion channels |
| 02/27/2003 | WO2003016489A2 Porcine leptin protein, antisense and antibody |
| 02/27/2003 | WO2003016487A2 Mammalian relaxin receptors |
| 02/27/2003 | WO2003016480A2 Tgf-$g(a) polypeptides, functional fragments and methods of use therefor |
| 02/27/2003 | WO2003016479A2 Excitatory glycine receptors and methods |
| 02/27/2003 | WO2003016478A2 G-protein coupled receptor polynucleotides and methods of use thereof |
| 02/27/2003 | WO2003016472A2 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 02/27/2003 | WO2003016466A2 ANTI-Aβ ANTIBODIES |
| 02/27/2003 | WO2003016464A2 Cancer specific oligosaccharide sequences and use thereof |
| 02/27/2003 | WO2003016351A2 N - cam related compounds modulating cell groth |
| 02/27/2003 | WO2003016348A2 A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine |
| 02/27/2003 | WO2003016347A1 Method of preparing peptide fragment having cell death inhibitory activity |
| 02/27/2003 | WO2003016345A1 Regulation of human regulator of g-protein signaling |
| 02/27/2003 | WO2003016341A2 Regulation of iron uptake |
| 02/27/2003 | WO2003016340A1 Derp1 and proderp1 allergen derivatives |
| 02/27/2003 | WO2003016339A1 A frog skin antibacterial peptide derivative |
| 02/27/2003 | WO2003016337A1 Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope |
| 02/27/2003 | WO2003016335A2 Irreversible cysteine protease inhibitors of legumain |
| 02/27/2003 | WO2003016333A2 Virus coat protein/receptor chimeras and methods of use |
| 02/27/2003 | WO2003016331A2 Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy |
| 02/27/2003 | WO2003016330A2 Molecular linkers suitable for crystallization and structural analysis of molecules of interest, method of using same, and methods of purifying g protein-coupled receptors |
| 02/27/2003 | WO2003016329A2 Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
| 02/27/2003 | WO2003016328A1 Methods for the treatment and prevention of cancer |
| 02/27/2003 | WO2003016273A2 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 02/27/2003 | WO2003015831A1 Gas microsphere liposome composites |
| 02/27/2003 | WO2003015822A1 5-cnac as oral delivery agent for parathyroid hormone fragments |
| 02/27/2003 | WO2003015820A1 GnRH AGONIST COMBINATION DRUGS |
| 02/27/2003 | WO2003015814A1 New peptides and use thereof in therapeutic agents against feline fiv infection |
| 02/27/2003 | WO2003015812A2 Beta-amyloid-analogue-t-cell epitop vaccine |
| 02/27/2003 | WO2003015811A1 Process for obtaining a pharmaceutical composition |
| 02/27/2003 | WO2003015810A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 02/27/2003 | WO2003015809A2 Antimicrobial cationic peptides and formulations thereof |
| 02/27/2003 | WO2003015775A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 02/27/2003 | WO2003015768A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015755A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | WO2003015753A1 Liposome preparations |
| 02/27/2003 | WO2003015750A1 Propellant-based microparticle formulations |
| 02/27/2003 | WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | WO2003015747A1 Method to treat pulmonary hypoplasia in the newborn |
| 02/27/2003 | WO2003015716A2 Immunoglobulin e vaccines and methods of use thereof |
| 02/27/2003 | WO2003015714A2 Compositions and therapeutic methods for viral infection |
| 02/27/2003 | WO2003015712A2 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
| 02/27/2003 | WO2003015711A2 Combination motif immune stimulatory oligonucleotides with improved activity |
| 02/27/2003 | WO2003015710A2 Combined drug and csf removal therapies and systems |
| 02/27/2003 | WO2003015708A2 Composition and method for treating hiv infection |
| 02/27/2003 | WO2003015706A2 Borinic acid protease inhibitors |
| 02/27/2003 | WO2003015705A2 In situ immunization |
| 02/27/2003 | WO2003015697A2 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | WO2003015615A2 Treatment of muscular dystrophies and related disorders |
| 02/27/2003 | WO2003015612A2 Materials and methods to promote repair of nerve tissue |
| 02/27/2003 | WO2003015521A1 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 02/27/2003 | WO2003004098A8 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 02/27/2003 | WO2003001881A3 Cell-based high-throughput screening methods |
| 02/27/2003 | WO2003000894A9 Polynucleotide vaccine |
| 02/27/2003 | WO2003000656A3 Antisense modulation of transforming growth factor beta receptor ii expression |
| 02/27/2003 | WO2002102986A3 Novel human transporter proteins and polynucleotides encoding the same |
| 02/27/2003 | WO2002099081A3 Methods of using colony stimulating factors in the treatment of tissue damage and ischemia |
| 02/27/2003 | WO2002099037A3 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| 02/27/2003 | WO2002098278A3 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002096398A3 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus |
| 02/27/2003 | WO2002092129A3 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
| 02/27/2003 | WO2002091992A3 Targeted delivery of drugs for the treatment of parasitic infections |
| 02/27/2003 | WO2002090518A3 Differential regulation of t cell survival and proliferation |
| 02/27/2003 | WO2002090325A3 Benzazepinone alpha v integrin receptor antagonists |
| 02/27/2003 | WO2002089744A3 Combined treatments and methods of treatment of mycoplasma and mycoplasma-like organism infections |
| 02/27/2003 | WO2002088172A3 Pentapeptide compounds and uses related thereto |
| 02/27/2003 | WO2002087511A3 Modulators of elastase inhibitor secretion |
| 02/27/2003 | WO2002086091A3 Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector |
| 02/27/2003 | WO2002083713A3 Echinocandin process |
| 02/27/2003 | WO2002080845A3 Novel eps8 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002080844A3 Novel bgp compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002079407A8 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |
| 02/27/2003 | WO2002077167A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 02/27/2003 | WO2002074957A3 Stress-responsive activator of p300 (strap) protein |
| 02/27/2003 | WO2002074794A3 Compositions useful in gene therapy |
| 02/27/2003 | WO2002074050A3 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |
| 02/27/2003 | WO2002072763A3 Nucleic acids, proteins, and antibodies |
| 02/27/2003 | WO2002072026A3 In situ langerhans cell vaccine |